The National Health Insurance Bureau will hold a meeting the day after tomorrow. Will there be new trends in drug collection?

Recently, a notice on convening a symposium on centralized drug purchase (hereinafter referred to as the notice) issued by the state health insurance bureau was circulated in the industry According to the notice, in order to implement the spirit of the executive meeting of the State Council and carry out the pilot work of national drug centralized procurement, it was decided to hold a symposium after research The contents of the meeting include introducing the basic ideas and implementation plans of the pilot work of national organization of drug centralized procurement, listening to local opinions and making arrangements for the recent work The participants include Beijing, Shanghai, Tianjin, Chongqing and Liaoning Guangdong, Fujian, Sichuan, Shaanxi and other provincial administrative departments in charge of drug recruitment and procurement, one in charge of centralized drug procurement center, one in charge of medical insurance department, one in charge of drug recruitment and procurement and one in charge of medical insurance department in Shenyang, Dalian, Guangzhou, Shenzhen, Xiamen, Chengdu, Xi'an and other cities, and one in charge of relevant national departments The meeting was held on August 3 Since its official listing on May 31 this year, the National Health Insurance Bureau has been called "super health insurance bureau" by the industry Its every action has attracted much attention The centralized purchase of drugs has always been the focus and hot spot of all sectors of the society, as well as one of the responsibilities of the health insurance bureau (to formulate the bidding and purchase policies for drugs and medical consumables and supervise the implementation), which is the most important concern For this conference on centralized drug procurement, although it is not clearly pointed out which kind of drug organization is the national centralized procurement, it is believed that from the recent policies, it is estimated that it is "the provincial special procurement of anticancer drugs in the medical insurance catalog and the pilot work of drug centralized procurement carried out by national organizations" Recently, the National Health Insurance Bureau said publicly that in 2017, 15 cancer drugs with definite efficacy but relatively expensive price, such as Herceptin, rituximab and Vanke, were included in the list of medical insurance drugs For the anticancer drugs in the catalogue, the next step will be to carry out special bidding procurement, and on the basis of fully considering the impact of tax reduction, realize price reduction through market competition As for the issue of how to reduce the price of anticancer drugs outside the medical insurance catalogue, the State Medical Insurance Bureau said that it would carry out access negotiations, negotiate with enterprises to determine a reasonable price to be included in the catalogue, and effectively balance the clinical needs of patients, the reasonable profits of enterprises and the fund bearing capacity Therefore, some analysts pointed out that the first shot by the state health insurance bureau is likely to be the provincial-level special procurement of anticancer drugs in the medical insurance catalog, as well as the pilot work of centralized drug procurement organized by the state As the new leader of drug bidding, what will happen to the centralized drug purchase led by the state health insurance bureau? How will the pilot work be carried out? According to the report of China's county health, it is pointed out that the procurement participation of pilot cities and medical consortia (medical institutions) will continue to strengthen, but the idea of classified procurement will continue For anticancer drugs and specialized drugs with large dosage, it is possible to carry out bulk purchase in the pilot mode, and for those with small dosage and some exclusive drugs, price confirmation or negotiation will be carried out At the same time, the filing procurement, matchmaking transaction and inquiry procurement will be normalized It is also believed that the bidding led by the National Medical Security Bureau must not only be based on price, but also on the principle of ensuring the quality of pharmaceutical products and considering the cost performance.